124c: Prophylactic Flap Reconstruction of the Knee Prior to Total Knee Arthroplasty in High Risk Patients

Abstract

Introduction: A living cell-based treatment (LCT; Apligraf®) consisting of human neonatal allogeneic keratinocytes and fibroblasts embedded in an extracellular matrix has been shown through multiple randomized controlled multicenter trials to improve the rate of healing of venous leg ulcers and diabetic foot ulcers. More limited data supports the notion that LCT can be used to improve the quality of healing by secondary intention. However, secondary intention healing in both cutaneous and mucosal environments is normally associated with prolonged time to healing, inflammation, pain and scar formation. Our hypothesis was that LCT could be used to modulate and improve the trajectory of secondary intention healing. We were particularly interested in the type and quality of tissue that could be produced.